50 results about "Low density lipoprotein cholesterol" patented technology

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention discloses a polysaccharide composition for treating hyperlipemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing phellinus linteus linteus, inonotus hispidus and boletus coratus and then performing water extraction. The polysaccharide composition provided by the invention can be used for reducing fat vacuolation and fat index, reducing the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increasing the content of high-density lipoprotein cholesterol by inhibiting the increase of weight and blood sugar of a hyperlipidemia mouse; the composition and abundance of intestinal flora are regulated and controlled, the intestinal flora disorder phenomenon is improved, the effect is better than that of single polysaccharide, and a new direction is provided for treatment for assisting blood sugar reduction.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

The invention discloses application of a group of blood nutrition markers in prediction of central nervous system (CNS) injury function prognosis. According to the technical scheme, the method is characterized in that serum albumin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) are determined as independent predictive factors of CNS injury prognosis for the first time through retrospective queue research (n = 404), and clinical decision critical values are determined to be 36.35 g / L, 3.60 mmol / L and 2.13 mmol / L respectively. The detection kit developed on the basis of the discovery can objectively and quantitatively evaluate the prognosis risk of the patient within 24 hours of admission, and is obviously superior to that of a traditional scoring system. According to the method, key technical support is provided for precise nutrition intervention and early rehabilitation strategy formulation of the CNS injury.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

A polyhydroxyalkanoate (PHA) containing monomer units of 3-hydroxybutyrate for use, by oral administration, in the prevention or treatment of an overweight or obesity condition, or of metabolic dysfunctions related to the condition. A marked effect was observed on the reduction of the body weight, both in the case of a standard diet and in the case of a diet rich in fats, a reduction that can be attributed to an increase in lipid oxidation to the detriment of the deposit of excess lipids, as confirmed by the decrease in the body weight and by analyses of the body composition. A positive effect on the metabolic dysfunctions related to an overweight or obesity condition has also been verified, in particular on dyslipidemias, such as the blood level of low-density lipoproteins (LDL cholesterol) and triglycerides, as well as an improvement in the inflammatory state.

The invention discloses compound safflower tea capable of reducing blood lipid. The compound safflower tea consists of the following components: 0.19 to 0.21 g of safflower, 0.195 to 2.050 g of American ginseng, 0.90 to 1.10 g of green tea, 1.10 to 1.20 g of hawthorn and 1.35 to 1.45 g of lotus leaf. According to the present invention, the C57BL / 6J mouse is subjected to the lipid-lowering experiment by using the safflower as the main material and using the American ginseng, the green tea, the hawthorn and the lotus leaf as the auxiliary materials, and the result shows that the safflower lipid-lowering tea can significantly reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C), can improve the liver fatty degeneration and the inflammatory reaction, and can alleviate the intestinal injury caused by the high fat diet; animal behavior experiments including Y maze, open field experiments and new object recognition experiments are used to verify that the safflower lipid-lowering tea has an improvement effect on mouse cognitive impairment caused by dyslipidemia.

This invention discloses an oil composition with a balanced fatty acid ratio and lipid-lowering effects, and its applications. The oil composition comprises vegetable oil, probiotics, phospholipids from camellia seed cake, gelatin, and sodium alginate. It effectively reduces serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels while increasing high-density lipoprotein cholesterol levels, exhibiting a good lipid-lowering effect. Furthermore, when the oil composition is formulated into microcapsules, it exhibits good stability, encapsulation efficiency, and release rate. The oil composition also helps maintain the activity of probiotics, allowing for better preservation and efficacy. Based on this, this invention also provides a candy containing the oil composition, enriching the variety of products with lipid-lowering effects and promoting the development of lipid-lowering related products.

The application discloses a polysaccharide composition for treating hyperlipidemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing Vansant yellow, Inonotus hispidus and Sarcodon fuligineus and then extracting with water. The polysaccharide composition can inhibit the increase of body weight and blood sugar of hyperlipidemia mice, reduce fat vacuolization and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder phenomenon, and the effect is better than that of single polysaccharide, thereby providing a new direction for the treatment of auxiliary blood sugar reduction.

Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent. Also, a method of preventing development of atherosclerotic cardiovascular disease in a subject involving administering to the subject a prophylactically effective amount of an RNAi agent. Further, a method of treating a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent involving administering to the subject a therapeutically effective amount of an RNAi agent.

This invention provides the use of RNA interferants that inhibit PCSK9 synthesis in prophylactic or therapeutic methods. [Solution] A method for reducing low-density lipoprotein cholesterol or preventing cardiac events in a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Also, a method for preventing the onset of atherosclerotic cardiovascular disease in a subject, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Furthermore, a method for treating a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a therapeutic effective amount of RNAi to the subject.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

This invention relates to compounds of Formula I and their isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, hydrates, prodrugs, and polymorphs. The compounds of Formula I can be used as inhibitors of proprotein convertase subtilisin 9 (PCSK9), effectively inhibiting PCSK9 activity and reducing the concentration of low-density lipoprotein cholesterol in plasma, and have good application prospects in the preparation of drugs for the treatment or prevention of cardiovascular diseases.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating cardiovascular diseases and a preparation method thereof.The traditional Chinese medicine composition comprises astragalus membranaceus, salvia miltiorrhiza, ligusticum wallichii, hawthorn, the root of kudzu vine, angelica sinensis, polygala tenuifolia, allium macrostemon, rhodiola rosea and euonymus alatus, and the preparation method comprises the steps that S1, medicinal materials are pretreated; s2, performing grouping extraction; s3, combining the extracting solutions; s4, purifying; and S5, drying. According to the scheme, winged euonymus twig is introduced, and the unique active ingredient dulcitrin contained in the winged euonymus twig can form a multi-dimensional synergistic system of tonifying qi, activating blood, activating yang and resisting oxidation with the medicinal materials such as astragalus membranaceus and salvia miltiorrhiza; experimental data show that the total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) of the traditional Chinese medicine composition containing the ramulus euonymi are obviously reduced, it is proved that the ramulus euonymi can enhance the synergistic effect of lowering lipid and improving hematorheology, and the problem that a traditional prescription is insufficient in regulating blood lipid strength is solved.

The present application relates to a kind of fish oil polypeptide composition for reducing blood fat and its application, belong to the field of biological medicine and functional food.The composition includes fish oil and pumpkin seed source active peptide C2-1 (molecular weight <3kDa), wherein active peptide accounts for 1-5% of the total weight of composition.Its preparation method includes: pumpkin seed protein complex zymolysis, ultrafiltration separation, anion exchange chromatography purification obtains C2-1 active peptide (KRGGRFL), then with fish oil homogenization into stable dispersion.The composition significantly reduces serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) by simultaneously inhibiting cholesterol esterase and lipase activity, and improves high-density lipoprotein cholesterol (HDL-C).Animal experiments show that its lipid-lowering effect is better than single fish oil, and is comparable to chemical drugs.The present application first realizes polypeptide-fish oil synergistic effect, provides safe and efficient new scheme for hyperlipidemia prevention and treatment.

The invention discloses dry chemical test paper for detecting low-density lipoprotein cholesterol and application of the dry chemical test paper. The dry chemical test paper for detecting low-density lipoprotein cholesterol comprises a supporting layer (1), a blood filtering layer (2), a diffusion layer (3), a filtering layer (4), a reaction layer (5), absorbent paper (6), detection holes (7) and a bottom plate (8). The filter layer of the dry chemical test paper adopts a lateral chromatography layout, so that the contact time of a sample and the filter layer is prolonged, the reaction activity of non-LDL components is fully inhibited, the detection reliability and accuracy are improved, the dry chemical test paper innovatively and reversely utilizes an asymmetric membrane, an inverted structure is formed in the reaction process, and the detection sensitivity is improved. The side, far away from the surface of the reaction layer, of the filter layer is of a small-aperture asymmetric structure, and the side, close to the surface of the reaction layer, of the filter layer is of a large-aperture asymmetric structure, so that an LDL-c sample with higher concentration can be accurately measured.

The invention belongs to the technical field of feed additives, and particularly relates to a chicken feed additive for relieving the fatty liver syndrome of laying hens and application of the chicken feed additive. The chicken feed additive is added into daily ration of laying hens; in the daily ration of the laying hens, the addition amount of the tartary buckwheat flavone is 40 mg / kg to 80 mg / kg, and the addition amount of the 25-hydroxy vitamin D3 is 1760 IU / kg to 3760 IU / kg. The chicken feed additive disclosed by the invention can relieve the fatty liver syndrome of laying hens, remarkably reduce the serum level of low-density lipoprotein cholesterol, triglyceride, free fatty acid and malondialdehyde, and remarkably enhance the activity of glutathione peroxidase and superoxide dismutase in the liver at the same time; gene expression associated with fat synthesis and inflammation is significantly inhibited, intestinal microbiota is remodeled, and lipid metabolism homeostasis is maintained to alleviate the fatty liver syndrome of laying hens.

The invention belongs to the technical field of medical chemistry, and particularly relates to a preparation method and application of eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. According to the preparation method of the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester, provided by the invention, 2-(3-indolyl) ethanol and eicosapentaenoic acid are used as raw materials, and lipase is added to react and synthesize the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. The eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester prepared by the preparation method disclosed by the invention has an excellent and comprehensive lipid-lowering effect, not only can effectively reduce the contents of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum, but also can effectively increase the level of high-density lipoprotein cholesterol. Meanwhile, the compound also has a strong direct blood vessel protection effect, can remarkably repair vascular endothelial dysfunction caused by high-fat diet and effectively recover endothelium-dependent vasodilatation capability, and is a safe and effective novel cardiovascular disease medicine.

The present invention relates to a lipid-lowering small-molecule peptide and its use. The lipid-lowering small-molecule peptide has the sequence LPSYSNAPYI and effectively inhibits pancreatic lipase activity and preadipocyte differentiation. This lipid-lowering small-molecule peptide can reduce levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol, while promoting an increase in high-density lipoprotein cholesterol. Furthermore, this lipid-lowering small-molecule peptide has been shown to be highly safe through cytotoxicity testing.

The present invention relates to a tartary buckwheat protein-derived lipid-lowering peptide and its use. The tartary buckwheat protein-derived lipid-lowering peptide has one or more of the following sequences: FHWDYPQA; FHWDYPQALE; LFHWDYPQA. This tartary buckwheat protein-derived lipid-lowering peptide has excellent pancreatic lipase inhibition, effectively inhibiting preadipocyte differentiation, and has the ability to lower total cholesterol, triglycerides, and low-density lipoprotein cholesterol, while increasing high-density lipoprotein cholesterol. Furthermore, the tartary buckwheat protein-derived lipid-lowering peptide is non-toxic and highly safe.

The utility model relates to the technical field of kits, and discloses a low-density lipoprotein cholesterol detection kit which comprises a storage box, anti-collision sleeves are fixedly mounted at four corners of the storage box, at least two slots are formed in the inner edge of the storage box, an insertion plate is mounted on the storage box in an insertion manner through the slots, and the anti-collision sleeves are fixedly mounted on the insertion plate. A first storage rack and a second storage rack are arranged in the storage box, a first storage groove and a second storage groove are formed in the first storage rack and the second storage rack in a penetrating mode, and a first turning cover and a second turning cover are rotationally installed on the outer edge of the storage box. According to the low-density lipoprotein cholesterol detection kit, the first protruding blocks and the second protruding blocks on the inner side of the turning cover correspond to the first storage grooves and the second storage grooves in a one-to-one mode, when the turning cover is closed, the protruding blocks can tightly press bottle caps of reagent bottles, elastic buffering fixing is formed, and the reagent bottles can be prevented from shaking up and down in the transportation process; and the storage grooves I distributed at equal intervals and the storage grooves II with larger diameters can be respectively matched with small-dose reagent bottles and large-dose reagent bottles, so that the modularized storage of the detection kit is realized.

The utility model relates to the technical field of cholesterol detection kit, and disclose a kind of small and dense low-density lipoprotein cholesterol detection kit, including storage box, first placement component and second placement component, at least two storage grooves are set in the storage box, the first placement component and second placement component are placed in the storage box by storage groove, hinge is set at the outer side of storage box, the other end of hinge away from storage box is provided with top cover, the first placement component includes the placement groove being set in the placement frame. The small and dense low-density lipoprotein cholesterol detection kit, support seat is fixed to the both sides of hinge, when opening top cover, support top cover can keep the angle of inclination, avoid top cover after completely opening and storage box collision, anti -skid line increase the friction between support seat and table top, prevent storage box from sliding in operation, the front handle of storage box and the top handle of top cover form bidirectional gripping structure, the design of two handles, it is convenient for user to take better.

The invention discloses exosome vesicle nano-selenium as well as a preparation method and application thereof, the exosome vesicle nano-selenium is prepared by adopting a lactic acid bacteria strain YKX which is screened out from a selenium-rich area and has a high nano-selenium conversion rate, and the influence of the exosome vesicle nano-selenium on mouse glycolipid metabolism disorder based on intestinal flora is studied; results show that the nano-selenium slows down weight increase and obesity of mice to a certain extent; the content of total cholesterol, total triglyceride and low-density lipoprotein cholesterol in serum of obese mice is reduced, and the content of high-density lipoprotein cholesterol is obviously increased; secondly, the intervention of the nano-selenium slows down the increase of the abundance of the mouse intestinal tract thick-wall mycophylum induced by high diet to a certain extent at the phylum level, improves the abundance of bacteroides and the overall diversity of the intestinal flora of the mouse, and improves the disorder of the intestinal flora; and finally, the nano-selenium intervenes in a metabolite level of intestinal microorganisms, so that the content of short-chain fatty acid is increased.

The present invention relates to a lipid-lowering peptide and its use. The lipid-lowering peptide has the sequence: NAIIGPRW, and can reduce the levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol, while also increasing the level of high-density lipoprotein cholesterol. Oil Red O staining experiments have shown that the lipid-lowering peptide of the present invention can effectively inhibit preadipocyte differentiation and has the ability to inhibit pancreatic lipase activity. Toxicity experiments have shown that the lipid-lowering peptide of the present invention is also highly safe.

The invention relates to a blood fat reducing fish oil polypeptide composition and application thereof, and belongs to the field of biological medicine and functional food. The composition comprises fish oil and pumpkin seed active peptide C2-1 (the molecular weight is less than 3kDa), wherein the active peptide accounts for 1-5% of the total weight of the composition. The preparation method comprises the following steps: performing composite enzymolysis on pumpkin seed protein, performing ultrafiltration separation, performing anion exchange chromatography purification to obtain C2-1 active peptide (KRGGRFL), and homogenizing the KRGGRFL and fish oil to obtain the stable dispersion. The composition significantly reduces serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) by synchronously inhibiting cholesterol esterase and lipase activity, and improves high density lipoprotein cholesterol (HDL-C). Animal experiments show that the lipid-lowering effect of the fish oil is superior to that of single fish oil and is equivalent to that of chemical drugs. The polypeptide-fish oil synergistic interaction is realized for the first time, and a safe and efficient new scheme is provided for hyperlipidemia prevention and treatment.

The invention provides application of SPPARMs in treatment of atherosclerosis, and belongs to the technical field of biological medicine. An ApoE gene knockout mouse is subjected to high-fat feeding to construct an atherosclerotic mouse model, THP-1 macrophages are exposed to oxidized low-density lipoprotein to construct a macrophage foaming model, INT131 is used for drug administration to an animal model and a cell model, and results show that INT131 can effectively relieve formation of atherosclerotic plaques, and can be used for treating atherosclerotic plaques. The content of AS mouse serum total cholesterol and low-density lipoprotein cholesterol is obviously reduced, and the content of high-density lipoprotein cholesterol is increased. In addition, INT131 can reduce intake of lipid in macrophages, promote cholesterol excretion and cholesterol metabolism, and inhibit formation of foam cells by inhibiting inflammatory response.